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Available online at
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www.sciencedirect.comIn this issue of as a Hot Topic in geriatric medicine, Gasowski
and Piotrowicz review current views on hypertension in older
patients [1]; is the paradigm really changing? In our comment, we
focus on the central study in this discussion, namely the American
Systolic Blood Pressure Intervention Trial (SPRINT [2]; not to be
mixed with the European Sarcopenia and Physical Frailty in Older
People: multi-component treatment strategies [SPRINTT] [3]),
which tested whether lowering systolic blood pressure below
120 mm Hg vs. below 140 mm Hg would bring further cardiovas-
cular benefits in hypertensive people without diabetes. The overall
results of SPRINT showed this really be the case: important clinical
cardiovascular endpoints including total mortality were reduced in
the intensive-treatment group [3].
The results in SPRINT participants aged 75 years and older
(mean age 79.9 years) [4] – a pre-specified subgroup – are useful to
answering several concerns that geriatricians have had about
potential adverse effects of antihypertensive treatment, especially
if performed intensively. SPRINT provided several answers to these
questions showing that cardiovascular disease outcomes and total
mortality were reduced also among older patients with intensive
treatment. Falls, orthostatic hypotension, and most other potential
side effects were not different in the 2 treatment groups, with the
exception of kidney side outcomes, which were increased in the
intensive treatment group [4].
In addition to adverse effects, a further concern when treating
older hypertensive patients has been that randomized trials would
only include fit older persons and results could not be applied to
older frail persons. A strength of SPRINT was that frailty status was
assessed [5] and results were not different according to frailty
level, supporting the HYpertension in the VEry elderly Trial
(HYVET) which also showed similar outcome [6].
Still, we have to point out that, similarly to HYVET, SPRINT
excluded the most frail subjects and several other subgroups of
patients with very frequent age-related disease such as patients
with type 2 diabetes, history of stroke, symptomatic heart failure
prior to inclusion, dementia, orthostatic hypotension (systolic
blood pressure of < 110 mmHg after 1 minute of standing), as well
as patients living in nursing homes. Therefore, individuals aged
75 years and older without the above diseases and conditions –
who nevertheless represent the majority of this age-group – are
benefitting by these important new findings of SPRINT.
However, one final concern about antihypertensive
treatment – and its intensity – in older people remains. As SPRINT
investigators point out, the results cannot be extrapolated to very
old, very frail individuals, such as those living in nursing homes
and in those with several cardio-metabolic or cognitive disorders.http://dx.doi.org/10.1016/j.eurger.2017.05.005
1878-7649/C 2017 Published by Elsevier Masson SAS.In addition to the current review, the specific problems of these
patients have been recently highlighted in an expert statement
[7]. But how to study them in a randomized trial setting? One
possibility is a ‘‘reverse’’ trial, discontinue treatment in those with
polypharmacy and low blood pressure levels and watch for
outcomes such as mortality, cognitive function and quality of life.
This type of studies are not without technical problems
(antihypertensive drugs are used for several indications, compet-
ing mortality is high), but from an ethical and medical point of view
they are supported by observational data of a significant
interaction between low blood pressure and higher mortality
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